Context Therapeutics (Nasdaq: CNTX) has paid USD 6.5 million to buy out all future milestone and royalty obligations on CT-202, its Nectin-4 x CD3 T cell engager, converting the original exclusive license from BioAtla (Nasdaq: BCAB) into a fully paid-up, non-terminable agreement. The amendment, announced May 18, 2026, closes out all remaining financial obligations to BioAtla under the original deal signed September 23, 2024, and arrives ahead of a Phase I trial initiation Context expects in Q3 2026.
The buyout is structured as two cash payments: USD 4.5 million paid at signing and a second USD 2.0 million due by August 1, 2026. The original license terms — including the specific milestone and royalty schedule that has now been extinguished — were not disclosed at the time of the 2024 agreement and remain undisclosed.
Deal context
CT-202 is a bispecific T cell engager targeting Nectin-4 on tumor cells and CD3 on cytotoxic T cells. The molecule is built on BioAtla's Conditionally Active Biologic (CAB) platform, which engineers antibodies to remain largely inactive at normal physiological pH (~7.4) and become active in the acidic tumor microenvironment (pH ~6.0–6.5). According to BioAtla's published platform description, this pH-dependent switching is driven by protonation of negatively charged residues that otherwise interfere with target binding — a reversible mechanism that, in preclinical models, has demonstrated differential binding ratios of roughly 9-fold to more than 175-fold between acidic and normal pH conditions.
Nectin-4 is a clinically validated oncology target: the ADC enfortumab vedotin targets the same antigen and carries US FDA approval in urothelial carcinoma. Context is pursuing CT-202 across bladder, breast, lung, and broader solid tumor indications. The company describes CT-202 as preferentially active within the tumor microenvironment, a design intended to reduce the on-target, off-tumor toxicities — including neuropathy and rash — associated with systemic Nectin-4 targeting. Context presented preclinical data on CT-202 at the American Association for Cancer Research Annual Meeting in April 2026. The Phase I trial record is listed on ClinicalTrials.gov as NCT07545122.
For Context, the transaction converts a contingent liability of unknown size into a fixed, capped cost. If CT-202 reaches commercialization, the economics of having eliminated royalties at this stage could be material. The trade-off is that Context assumes full development cost and risk with no ongoing BioAtla participation.